Denali Therapeutics Inc. Annual Operating Income (Loss) in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Denali Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2023.
  • Denali Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$123M, a 8.25% decline year-over-year.
  • Denali Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$490M, a 189% decline year-over-year.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$197M, a 42.3% increase from 2022.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$341M, a 15.2% decline from 2021.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$296M, a 572% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$197M +$144M +42.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$341M -$45M -15.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$296M -$358M -572% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $62.7M +$276M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$213M -$167M -360% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$46.4M +$43.8M +48.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$90.1M -$2.71M -3.1% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$87.4M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.